Efficacy of human lyme disease vaccine formulations in a mouse model

S. R. Telford, F. S. Kantor, Y. Lobet, Stephen W Barthold, A. Spielman, R. A. Flavell, E. Fikrig

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Although immunization with recombinant outer surface protein A (OspA) appears to protect mice against infection by the agent of Lyme disease, all reported experiments have involved formulations that would not be suitable for use in humans or have not used realistic challenges. This study was designed to determine whether vaccines prepared and used in a phase I human trial, including one currently being used for a phase II trial in sites with endemic Borrelia burgdorferi, conferred protection in the C3H/HeJ mouse model. The challenge was ticks collected from a major site of the trial. None of the vaccinated mice became infected or developed disease, whereas 60% of unvaccinated mice became infected. Spirochetes were destroyed within the guts of virtually all recovered challenge ticks. These preparations of recombinant OspA effectively induced immunity to protect mice from Lyme disease when bitten by ticks collected from a field trial site.

Original languageEnglish (US)
Pages (from-to)1368-1370
Number of pages3
JournalJournal of Infectious Diseases
Issue number5
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Efficacy of human lyme disease vaccine formulations in a mouse model'. Together they form a unique fingerprint.

Cite this